Caladrius Biosciences, Inc. (Caladrius, formerly NeoStem) is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market.
Company Growth (employees)
Allendale, US
Size (employees)
221 (est)
Caladrius was founded in 2006 and is headquartered in Allendale, US

Caladrius Office Locations

Caladrius has offices in Allendale, Mountain View
Allendale, US (HQ)
4 Pearl Ct
Mountain View, US
291 N Bernardo Ave

Caladrius Metrics

Caladrius Financial Metrics

Revenue (2016)

$35.3 m

Revenue growth (2015-16), %


Gross profit

$4.1 m

Gross profit margin (2016), %


Net income (2016)

($33.3 m)

Market capitalization (01-Sep-2016)

$28.3 m

Closing share price (01-Sep-2016)


Cash (31-Dec-2016)

$14.7 m
Caladrius's current market capitalization is $28.3 m.
Caladrius's revenue was reported to be $35.3 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016


$14.7 m$17.9 m$22.5 m$35.3 m

Revenue growth, %


Cost of goods sold

$12.9 m$15.7 m$20.2 m$31.1 m

Gross profit

$1.7 m$2.3 m$2.3 m$4.1 m

Gross profit Margin, %



($36.8 m)($57.7 m)($113.8 m)($31.3 m)

EBIT margin, %


Net Income

($39.5 m)($55.5 m)($81 m)($33.3 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$46.1 m$19.2 m$20.3 m$14.7 m

Accounts Receivable


$1.3 m

Current Assets

$50.8 m$36.3 m$29.3 m$24.6 m


$12.8 m$16 m$17.1 m$17.1 m


$11.1 m$25.2 m$7 m$7 m

Total Assets

$89.8 m$126.3 m$57.2 m$51.8 m

Accounts Payable

$3.4 m$5.7 m$4.1 m$4.4 m

Total Debt

$3.4 m$2.4 m$584.4 k

Current Liabilities

$9.8 m$16.2 m$21 m$19.5 m

Additional Paid-in Capital

$299.6 m$350.4 m$396.5 m$410.4 m

Retained Earnings

($236.4 m)($291.2 m)($372.1 m)($404.8 m)

Total Equity

$62 m$58.1 m$23.3 m$4.1 m

Debt to Equity Ratio

0.1 x0.1 x0.1 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

1.4 x2.2 x2.5 x12.7 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($39.5 m)($55.5 m)($81 m)($33.3 m)

Depreciation and Amortization

$1.6 m$2.2 m$2.7 m$2.7 m

Accounts Receivable

($573 k)($1.2 m)$545.2 k($325.6 k)


($758.8 k)($2.8 m)

Accounts Payable

Cash From Operating Activities

($27.1 m)($46.9 m)($39.3 m)($23.7 m)

Purchases of PP&E

($2.7 m)$3.7 m$3.2 m($2.8 m)

Cash From Investing Activities

($2.7 m)($10.7 m)$3.8 m($2.8 m)

Long-term Borrowings

($9.3 m)

Interest Paid

$274.1 k$232.5 k$1.5 m$1.8 m

Income Taxes Paid

Caladrius Online Presence

Caladrius Company Life

You may also be interested in